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Chlamydia trachomatis is an obligate intracellular bacterium that is the cause of
a wide spectrum of human disease including trachoma, inclusion conjunctivitis,
pneumonia, lymphogranuloma venereum, and genital tract infections such as
urethritis and cervicitis (1). The most damaging sequelae from these infections
are sterility and, in trachoma endemic areas, blindness . Both severe outcomes
are caused by immunopathology thought to result from a sensitizing antigen
presented during repeated or persistent infection (2) .
Immunity to chlamydial infections is poorly understood . Innonhuman primate
models (3) and in early human vaccine trials (4) using preparations of intact
organisms, immunity was characteristically serovar specific, secretory antibody
mediated, T cell dependent, and relatively short lived, although dose dependent .
Reinfection of individuals after vaccine failure, either from inadequate vaccine
potency or by infection with a serovar different from that contained in the
vaccine, resulted in more severe disease than controls (5) . The serovar specificity
of immunity is particularly challenging since >15 serovars of C . trachomatis have
been defined by serological analyses (6) andmAb probes (7, 8) . New approaches
toward vaccine development for these organisms must take into account their
antigenic diversity, and define and separate antigens that elicit immunity from
those that are responsible for immunopathology .
The major outer membrane protein (MOMP)' of chlamydiae is the principle
protein surface component (9), has functional roles for the structural integrity
of the extracellular infectious form (10, 11), and pore-forming capabilities that
permit exchange of solutes for the intracellular vegetative form (12) . Unlike
outermembrane proteins or porins described forother bacteria, these functional
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attributes of chlamydial MOMP are regulated by the oxidation and reduction of
intra- and intermolecular disulfide bonds (12). The MOMP is also antigenically
complex, and this protein is the focus of immune responses that have been
associated with protective immunity. Each MOMP displays serovar-specific and
common antigens, suggesting that a single molecule possess both variable and
constant antigenic domains (7, 13). This has been demonstrated by structural
studies (14), mAb studies (7, 15), and is compatible with DNA sequence compar-
isons between MOMP genes (ompl) from three different serovars. These ompl
comparisons reveal four variable sequence domains and five highly conserved
domains (16).
The various specificities of mAbs to MOMP include serovar specific, those
that bind one (or two closely related) serovars; subspecies specific, those that
bind between 4-12 serovars; and species specific, those that bind all 15 serovars.
The purpose of this investigation was to map the major topographic antigenic
determinants of MOMP that have been defined by mAbs. Using recombinant
DNA techniques and peptide synthesis we have mapped the linear distribution
of two antigenic domains; one domain contains a serovar-specific antigenic
determinant while the other domain contains subspecies-specific determinants
and a species-specific determinant. Preliminary data concerning the subspecies-
and species-specific antigenic domains have been reported in the proceedings of
a recent symposium (17). Our current evaluations defined sequence-specific
determinants that may be used for studies of structural and conformational
attributes of this multifunctional protein, and for immunological studies. Fur-
thermore, these defined determinants may have important applications for the
development of seroepidemiological and immunodiagnostic assay systems.
Materials and Methods
Organisms. Two C. trachomatis ocular strains, B/TW-5/OT, C/TW-3/OT, and one
LGV strain, L2/434/Bu, were grown and purified as previously described (18). The agtI l
expression vector system has been described (19). A XgtlI recombinant, L2/33, that
expressesa serovar L2 COOH-terminal MOMP fusion productin Escherichia coli hasbeen
described (20).
Antibodies.
￿
Polyvalent antisera to C. trachomatis serovars L2, B, or C were obtained
from rabbits immunized with purified organisms as previously described (21). Monospe-
cific antisera to synthetic peptide conjugates were produced in rabbits as previously
described (22). The development, specificities, and ascites production for mAbs to
chlamydiae have been previously reported (7).
Construction of Recombinant Phage.
￿
Restriction endonuclease fragments from the
MOMP genes from serovars L2, B, and C (ompIL2, omplB, and omp1C) were inserted in
reading frame into the,8-galactosidase gene in agt11 as previously described (20). Plaques
from these constructions were screened with polyvalent antisera or mAbs, and immune
reactionswere detected usingperoxidase-conjugated antisera as previously described(20).
Lysogens of selected recombinants were produced as previously described (19, 20).
Immunological Characterizations.
￿
Immunoblotting of chlamydial lysates or E. coli lyso-
gens were performed by the method of Towbin et al. (23) with modifications described
previously (20). ELISA assays were performed after adsorption of chlamydial organisms
(40 gg/ml), lysogenlysates (100,ug/ml), synthetic peptides (50F,g/ml), or synthetic peptide
conjugates (20 ug/ml) to 96-well microtiter plates overnight at 4°C in PBS, pH 7.6, as
previously described (7), except immune reactions were detected using peroxidase-con-
jugated antisera and o-phenylenediamine substrate. Microimmunofluoresence (micro-IF)
assays were performed as previously described (6).STEPHENS ET AL.
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DNA Sequencing.
￿
DNA inserts from antibody-reactive Xgtl l recombinants were sub-
cloned into M13mp18 and sequenced by the dideoxy method as previously described
(24) .
Peptide synthesis.
￿
Peptides were synthesized by solid-phase techniques and conjugated
to thyroglobulin as previously described (22) . The polypeptides chosen for synthesis were
based upon the results of antigenic domain locations using recombinant DNA techniques
for ompIL2, described herein, and amino acid sequence comparisons for analogous
sequences for omp1B and omplC (16, 24) .
Results
Strategy for Mapping Antigenic Determinants.
￿
The strategy used for mapping
antigenic determinants of MOMP is shown in Fig . 1 . The ompIL2 structural
gene contains three Eco RI restriction endonuclease sites and a fourth Eco RI
site is located 659 by from the 3' end of the open reading frame (24), thus the
gene can be separated into three mutually exclusive Eco RI fragments denoted
in Fig . 1 as 1, 2, and 3 (131, 498, and 1,102 bp, 5'-3' respectively) . Xgt11 fusion
products from each of these three fragments were evaluated for antigenicity
using polyvalent antisera that were obtained after immunizations with purified
organisms . In separate experiments, each DNA fragment was further cleaved
with Alu I or Rsa I and these fragments were similarly cloned into XgtII and
assayed .
Subclones that produced fusion peptides recognized by polyvalent antisera
were sequenced, thus permitting localization of each antigenic fusion peptide
along the gene . Polypeptide sequences identified from these clones were synthe-
sized and evaluated for antigenicity using various antisera and mAbs, and tested
for immunogenicity in rabbits . After characterization ofompIL2, analogousgene
fragments from serovars B andC were constructed or synthesized and evaluated .
Two Immunodominant Antigenic Domains .
￿
In a previous report, Stephens et al .
(20) described expression of a COOH-terminal portion of the MOMP gene from
serovar L2 (fragment 3, Fig . 1) in Xgtll . This recombinant was designated
gtll/L2/33 and species-specific and subspecies-specific mAbs each recognize
determinants on this fusion product . It was also reported that two serovar-specific
mAbs 2H2 and 2H5, bound this product . Subsequent evaluations by Stephens
FIGURE 1 . The bold hori-
zontal line represents the
ompIL2 open reading frame .
The relative positions of re-
strictionendonuclease sites for
Eco RI (E) are shown above
the line and sites for Alu I (A)
andRsa I (R) areshownbelow
the line . The brackets above
the line delineate the three
EcoRI fragments (1, 2, and 3)
used to produce XgtI I fusion
products. Open boxes, de-
noted 2' and 3', show the lo-
cation of the Alu I or Rsa I
restriction fragments that
were selected after cloning
and expression .820
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FIGURE 2.
￿
Composite of immunoblots of lysates
of agtI l lysogens and lysates of chlamydia orga-
nisms . (Lane 1) agtII without insert DNA; (lane
2) serovar LsEco RI 2 lysogen ; (lane 3) chlamydia
organisms homologous to the respective antisera
(plate L2, B, or C) . Each blot was probed with one
rabbit polyvalent antiserum that was specific to
either serovar LY (Ls), serovar B (B) or serovar C
(C) organisms (see Materials and Methods). Each
antiserum recognized several common antigenic
components and the MOMP (small arrow) of its
homologous serovar, but only antiserum specific
to serovar L2 recognized the fusion product Eco
RI 2 (bold arrow, I,ft panel).
and Wagar (17) have revealed the latter observation to be in error; one antibody
was later found not to be serovar specific and the other was found to bind fl-
galactosidase nonspecifically . Thus, this COON-terminal fragment does not
encode serovar-specific antigens but does encode subspecies- and species-specific
determinants . Consequently, the search for the serovar-specific domain was
approachedby cloning each of thetwoEco RI restriction endonuclease fragments
(fragments I and 2, Fig. 1) that are located upstream from the 3' Eco RI
fragment (fragment 3, Fig. 1) . The sequence 5' to the Eco RI 1 fragment encodes
primarily the conserved and processed leader sequence and was not evaluated
(24) .
Both fragment 1 and fragment 2 encoded antigens that were detected with
polyvalent antisera by the plaque assay and by immunoblot of corresponding
lysogens . The antigens encoded by fragment 1, however, were only detected
using an antiserum that was obtained from a rabbit immunized with purified
MOMP . This fusion product did not bind antibodies produced in rabbits that
were immunized with whole, purified organisms . This portion ofMOMP was
also not recognized by antiserum obtained from a patient with lymphogranuloma
venereum ; although the antiserum reacts strongly to L2 MOMP by immunoblot
(data not shown) . Since fragment I did not encode a natural immunogen, and
was probably not surface exposed, further evaluation of this fragment was not
pursued .
In contrast, the fusion product obtained from cloning fragment 2 was detected
by polyvalent antisera specific to serovar L2 organisms (Fig. 2), monospecific
antisera to serovar L2 MOMP, and the human sera described above (data not
shown) . Significantly, only weak reactivities were noted to the fusion product
from this fragment using serovar B-specific polyvalent antisera, and no reactivity
was observed using serovar C-specific polyvalent antisera (Fig . 2) . Evaluation of
the fragments with L2 serovar-specific mAbs (2171, 2B6, 2C3, 2A12 ; reference
7) showed strong signals with fragment 2, and mAbs specific for serovar B (1 B7)
or C MOMP (2B1) did not react (Fig . 3) . Thus, fragment 2 demonstratedSTEPHENS ET AL .
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FIGURE 3 .
￿
Immunoblots of serovar L2 agt11 lysogen
lysates for recombinants that expressed fragments 2, 2',
3, and 3' . Duplicate transfers were tested with a variety
of mAbs. A composite figure was made using only the
area of the nitrocellulose sheets that contained the fusion
proteins. mAb specificities (described in references 7 and
20) are given inparentheses below. Serovar-specific mAbs
lB7 (B) and 2B1 (C, J) did not bind serovar Lx fusion
products. Ls serovar-specific mAbs are represented by
2F1 . Additional serovar-specific antibodies that showed
the same profile included : 2B6, 2C3, and 2A12 . Addi-
tional subspecies-specific mAbs tested that displayed fu-
sion protein reactivities similar to 211E3 (LI, L2, B, Ba, E,
D) include : JG1 and KD3 (Ls, B, Ba, E, D) . Additional
subspecies-specific mAbs tested that displayed fusion pro-
tein reactivities similar to 2G3 (K, L,, LI , Ls, B, Ba, E, D)
include : 2G1 (H, K, Ls, Ls, B, Ba, G, F) and KG5 (H, K,
L,, LI , L2 , B, Ba, E, D, G, F) . Species-specificmAbs IH8
and2C5showed the same reactivities as 2C1 (recognizes
all serovars).
remarkable serovar-specific restriction in reactivity given that it encodes 166 of
the 372 (45%) amino acids for MOMP .
The coding regions of both Eco RI fragments 2 and 3 are large (498 and 443
bp, respectively), thus finer resolution of the specificities encoded by each of
these two fragments was sought by cleaving each fragment independently with
Alu I (and in some experiments with Rsa I) and cloning these fragments into the
XgtI I expression vector . Antibody-positive plaques were obtained only from Rsa
I digests of fragment 2 and Alu I digests of fragment 3 . The DNA from ^-10
positive plaques was sequenced with the result that all positive plaques from the
Eco RI 2 fragment had the sameDNA insert : a 110-bp Rsa I fragment that was
designated 2' (Fig . 1) . Similarly, all positive plaques from the Eco RI 3 fragment
had a single DNA insert (17) : a 48-bp Alu I fragment that was designated 3'
(Fig. 1) .
Plaques and immunoblots of lysogen lysates of the 2' sibling demonstrated the
same antibody specificities (i.e ., serovar specific) as those observed for the
respective parent Eco RI 2 clone (Fig . 3) . The recombinant product obtained
from the 3' sibling also demonstrated the same antibody specificities as those
observed for the Eco RI 3 parent (i.e ., subspecies and species specific) . Thus, for
serovar L2, the serovar-specific domain was mapped within a 38-amino acid
sequence and the species-specific and broadly reacting subspecies-specific anti-
gens were mapped within a 16-amino acid domain .
Stephens et al . (16) recently reported the comparative DNA and amino acid
sequence for the MOMP of each of the three serovars L2, B, and C . Fig. 4 shows
the sequence for each of these serovars within the antigenic domains mapped
using recombinant DNA techniques . An analogous serovar-specific Eco RI 2
fragment from serovar B was cloned into Xgt1I and this clone demonstrated822
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FIGURE 4 .
￿
Comparative amino acid sequences (16) andgene locations ofthe serovar-specific
and common antigenic domains of MOMP between serovars L2, B, andC . Blank spaces for
serovar B and C sequences denote identity to the serovar L2 sequence . Antibody-positive
products from restriction endonuclease fragments 2, 2', 3, and 3' are noted . The gene is
oriented 5'-3' and the amino acid sequences are oriented NH2-terminal-COOH-terminal
viewed left to right . Numbers indicate amino acids as previously described (24) .
reactivities only with homologous polyvalent antisera and B-specific mAbs (data
not shown) . Because of restriction site polymorphisms within this gene family, a
similar site is not present in the serovar C gene ; hence the fragment analogous
to the L2 2' fragment was cloned by synthesizing a 90-bp oligonucleotide based
upon the DNA sequence of omp1C. The fusion product from this construction
reacted only to the C-specific polyvalent antisera and C-specific mAb (data not
shown) .
High-Resolution Mapping of Species-speck and Subspecies-specific Determi-
nants. The antigenic domains defined by antibody-reactive fusion proteins
permitted us to focus on their amino acid sequences for the selection of peptides
to be synthesized, thus allowing confirmation and more circumscribed analysis
oftheir antigenic determinants . Twoparameters were evaluated: (a) comparative
amino acid sequences for the MOMPs of three antigenically distinct serovars,
and (b) hydrophilicity profiles of these sequences as described by Hopp and
Woods (25) for the prediction of antigenic determinants . The comparative
sequences of the fusion product obtained from fragment 3' that contains subspe-
cies- and species-specific antigenic determinants show that the majority of resi-
dues are conserved between the three serovars (Fig . 4), although serovar B hasSerovar-Specific Peptides
DNENHATVSDSKLV
￿
L2 Type
NNENQTKVSNGAFV B Type
TKTQSSS FNTAKL I C Type
141
￿
154
m
0
Antibodies
Rabbit anti-L2
Rabbit anti-B
Rabbit anti-C
2C1
￿
(all species-specific)
2G3 (H,K,L3,L1,L2,B,Ba,E,D)
2110 (L1,L2,B,Ba,E,D)
IVF1 (L2)
1B7 (B)
2B1 (CJ)
IL2 Type
Synthetic Polypeptides
B Type
￿
C Type
￿
SS1
￿
SS2
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ATTVFDVTTLNPTIAG SSt
DVTTLNPTIAG SS2
291
￿
306
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FIGURE 5. Synthetic poly-
peptides from the serovar-spe-
cific domain for serovars L2,
B, and C (labeled respectively)
and synthetic polypeptides for
the common antigenic domain
(SS1 and SS2) were tested by
ELISA using a spectrum of
polyvalent antisera and mAbs
(Materials and Methods).
Reactivities were scored as +
if a visual signal was detected
above that of the conjugate
control.
two differences compared with the serovar L2 sequence, and the more distantly
related serovar C sequence has four differences. The remaining consecutive I I
amino acids are conserved among each of the serovars.
Since these 16 amino acids represent at least two antigenic determinants, it
was reasoned that the conserved portion of this sequence may be associated with
the species-specific epitope, while the N112-terminal portion may be associated
with the subspecies-specific epitopes because of the sequence heterogeneity at
this location. The hydrophilicity profile of this segment was also compatible with
these assumptions (16). The NH2-terminal sequence is relatively hydrophilic,
which would be expected for subspecies-specific determinants since these reactiv-
ities are obtained relatively frequently among the spectrum of mAbs derived
from C. trachomatis (7). Obtaining species-specific mAbs is an infrequent outcome
(7), and this is consistent with the hydrophobic character of the conserved portion
of this sequence . It is thought that five to eight amino acids are required for
most linear protein epitopes; thus, to separate the reactivities observed for this
sequence, an 11-amino acid peptide was synthesized that was homologous to the
conserved region of the sequence and was designated SS2 . In addition, the entire
16-amino acid peptide was also synthesized (SS 1) to corroborate the fl-galacto-
sidase fusion data and as a control for antibody binding. These synthetic peptides
(and peptide conjugates) were tested by ELISA with a variety of mAbs. Three
reactivity profiles were observed (Fig. 5). Species-specific mAbs (2C I) bound
both the SS I and SS2 peptides. This demonstrated that the species-specific
determinant was bounded within the conserved 11-amino acid sequence. Sur-
prisingly, mAbs that characteristically display broad subspecies-specific reactivity
profiles (i.e., those that bind B-complex serovars in addition to one or more of
the C-complex serovars such as mAb 2G3) also bound both synthetic peptides.
This shows that these subspecies-specific and the species-specific epitopes are
overlapping, and that many ofthe unique subspecies-specific reactivities observed
in assays using intact organisms are not strictly linear and are modulated by824
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secondary or tertiary features that differ subtly among serovars. The third
pattern was represented by mAb 211E3, which bound only the SS I peptide. The
specificities of these antibodies are restricted to B-complex serovars (7). This
determinant must be located near the NH2-terminal portion of the domain
wherein the four-amino acid region of heterogeneity modulates the specificity
of these antibodies.
High-Resolution Mapping of Serovar-specific Determinants.
￿
The 24 NH2-termi-
nal amino acids for the serovar-specific domain defined by the 2' fusion product
are highly conserved (Fig. 4) and on average hydrophobic (16). The following
14 consecutive amino acids encompass ompl variable segment 2 (16), which is
the most highly sequence variable region of MOMP, and these are relatively
hydrophilic for each serovar (16). Consequently the latter 14-amino acid se-
quence for each of the three serovars was chosen for synthesis to assess their
potential for antigenic activity. Each peptide sequence reacted only to the
respective homologous polyvalent antisera or mAb (Fig. 5). Thus, a continuous
serovar-specific antigenic determinant of MOMP has been defined to a resolution
of 14 amino acids.
Immunogenic Characterization of Synthetic Peptides.
￿
Rabbits were immunized
with each of the synthetic peptide conjugates, except for the B-type peptide, and
the resulting antisera were evaluated by ELISA and micrr -IF assays. The anti-
SS1 and anti-SS2 peptide sera produced titers of ^" 1 :6,400 to their homologous
unconjugated peptides by ELISA. Similar ELISA titers were obtained using
chlamydial organisms. The anti-SS I or anti-SS2 sera also showed high titers and
bright fluorescence by micro-IF (1 :1,600) to all 15 serovars of C. trachomatis but
did not react to C. psittaci (Mn). Since both of thesepeptides contain the conserved
species-specific antigenic determinant these reactivities would be expected if this
sequence is immunogenic. It might also be expected that SSI would show
subspecies-specific reactivities at endpoint dilutions of antisera if the NH2-
terminal portion ofthe SS1 peptide were more immunogenic than the conserved
COOH-terminal portion, but this was not observed.
The anti-L2-type peptide and the anti-C-type peptide sera produced titers of
1 :800 and 1 :3,200 (respectively) to their homologous unconjugated peptides
by ELISA. The anti-L2-type peptide serum reacted to serovar L2 organisms and
not to serovar B or C organisms by ELISA. Anti-C type-peptide serum reacted
to serovar C organisms and not to serovars L2 or B. Unlike the anti-SSI and
-SS2 sera, binding of these type peptide sera produced consistently lower titers
to their homologous organisms than to the immunogen . Micro-IF evaluation of
the antiserum derived from the L2-type peptide showed binding only to serovar
L2 organisms with moderate fluorescent intensity (1:80). The anti-C-type peptide
serum displayed bright fluorescence and, at low dilutions (1 :80), showed cross-
reactivity to elementary bodies within the C-complex group (i .e. J, I, H, K, and
Ls), although at higher dilutions was specific to serovar C (Fig. 6). Serovar A is
also a member of the C-complex group; however, anti-C-type peptide serum did
not react to this serovar.STEPHENS ET AL .
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FIGURE 6.
￿
Micro-IF evaluation ofserum obtained from
a rabbit immunized with the serovarC type-peptide . Bars
show the titers and reactivities to each of the 15 serovars.
Discussion
Serological evaluations of C. trachomatis isolates have defined 15 serovars,
lettered A-K including Ba, L I , L2 , and Ls . Serological relationships separate the
serovars into B- and C-complex groups based upon observations of varying
degrees of crossreactivity among serovars within their respective groups and
limited crossreactivity among serovars from different groups (6) . Serovars L2 , B,
and C were chosen for study because the serological and molecular relationships
among these serovars are representative and exemplify the spectrum of antigenic
relatedness within the species . Serovars L2 and B are members of the B-complex
group and are closely related serologically (6) . Serovar C is a member of the C-
complex group and is the most divergent serovar (6) . When mAbs are prepared
against MOMP, species-, subspecies-, and serovar-specific determinants can be
discriminated on each of the 15 MOMPs (7, 15) . Thus theMOMP of chlamydiae
is antigenically complex, and DNA sequence comparisons among antigenically
distinct strains have shown that MOMP is a sequence variable protein within
defined domains (16) .
Species-specific Determinant .
￿
The MOMP species-specific determinant is de-
fined by mAbs developed by Stephens et al . (7) and these antibodies bind a
surface antigen that is represented for each of the C. trachomatis serovars . The
selection of antibodies with such specificities is, however, an uncommon event .
Thus it has been presumed that the native presentation of this antigen is poorly
immunogenic . Interestingly, the conserved 11-amino acid synthetic peptide
(SS2) bound by these antibodies elicited antisera with titers nearly equivalent to
both the immunizing peptide and intact organisms . This demonstrates that there
is a continuous species-specific antigenic determinant defined within this primary
amino acid sequence . The hydrophilicity profile for this sequenceand its flanking
sequence, suggest that this determinant may be restrained within a hydrophobic
cleft (16) . Therefore, the structural basis for the low immunogenicity of this
determinant within the native protein is related to low hydrophilicity (25), and
probably a lack of topographic protrusion (26) and low mobility (27) .
Species-specific mAbs have been shown to neutralize infectivity of chlamydiae
in vitro (28), thus, this immunogenically augmented peptide sequence may be a
candidate for the development of a chlamydial vaccine that would provide
protection against many serovars . Ofmore immediate significance is that species-826
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specific mAbs have been extensively used for culture-independent diagnostic
assays with high specificity and sensitivity (29). However, these assays are not
equivalent to culture systems, especially for the detection of asymptomatic
infections. Sequence-specific immunological reagents such as antipeptide mono-
specific sera, or mAbs, used in conjunction with their homologous peptide
provide the basis for the development of new competitive or homogeneous assay
systems that may substantially improve the culture-independent detection systems
currently available.
Two Subspecies-specific Determinants.
￿
Subspecies-specific determinants are de-
fined by mAbs that bind to usually four or more serovars (7). There have been
a number of these mAbs developed to the B-complex serovars that display only
minor differences in specificity, primarily because these serovars are closely
related serologically. Each member of the C-complex is serologically much more
distinct, although mAbs that bind to several or all C-complex serovars have been
described (8).
Each ofthe subspecies-specific mAbs evaluated in this study bound the 000H-
terminal common antigenic domain, and evaluation of synthetic peptides re-
vealed the antigenic complexities of this domain. Both subspecies-specific mAbs
and species-specific mAbs recognized the same 16-amino acid peptide (SS 1);
thus, this domain must represent a series of overlapping antigenic determinants.
A subset of subspecies-specific mAbs bound only the 16-amino acid peptide, and
these did not bind the truncated 11-amino acid peptide. The specificities o£ the
subspecies-specific mAbs tested that gave this pattern were limited to recognizing
only serovars within the B-complex group. This finding demonstrated that the
sequence diversity at the NH2-terminal end of the 16-amino acid peptide can be
attributed to modifying the specificities of this category of antibodies.
In contrast, other subspecies-specific mAbs bound both peptides, thus the I I-
amino acid sequence that is conserved among all serovars (and also bound by
species-specific mAbs) was sufficient for binding. The specificity profiles for these
mAbs are characterized by recognition of serovars in both the B- and C-complex
groups. These observations are consistent with the finding that, when the
specificities of subspecies-specific mAbs are compared between assays of whole
organisms and immunoblotting of denatured MOMP, some mAbs display the
same specificity pattern in both assay systems, while others bind all serovars only
by immunoblot analysis (30).
Our data have demonstrated at least three antigenic determinants clustered
within this 16-amino acid domain. Local stereochemistry and discontinuous
interactions as a result of higher ordered structural features of this protein, or
polymeric units of this protein (10, 11), account for the large variety of epitopes
defined by subspecies-specific mAb reactivities that have been observed among
C. trachomatis serovars. Clearly, this is a complex domain and the molecular basis
of the subspecies-specific determinants provides some rationale for understand-
ing apparent discrepancies in behavior of this class of mAbs in different assay
formats (30, 31).
Serovar-specific Determinants.
￿
Serovar-specific determinants have been shown
to be important for induction of immunity both in animal models and in human
vaccine trials (3, 4). Recently, Zhang et al. (31) have demonstrated that serovar-STEPHENS ET AL.
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specific mAbs to MOMP are capable of neutralizing C. trachomatis infection for
monkey eyes. The immunodominance of MOMP serovar-specific antigens is
evidenced by the serovar-specificity of immune polyvalent antisera at end-point
dilutions. Indeed, this attribute forms the basis of the seroepidemiological micro-
IF evaluations of chlamydiae (6, 8). mAb studies also support this observation in
that, of the various mAbs derived to MOMP, serovar-specific and subspecies-
specific are most frequently detected (7, 8).
We have located a continuous serovar-specific antigenic determinant within a
14-amino acid peptide sequence. Significantly, this sequence corresponds pre-
cisely to the most sequence variable domain based upon amino acid comparisons
of MOMP for these serovars (16) . The 14-amino acid peptide synthesized for
each of these serovars was recognized exclusively by serovar-specific mAbs and
only by homologous polyvalent antisera. Given the serovar-specific dominance
of this domain with polyvalent antisera, and as the sequences of more of the
serovars are obtained, constructions of these defined determinants may have
application toward the development of a rapid, inexpensive, and standardized
seroepidemiological assay system.
The use of these peptides as immunogens demonstrated that they were capable
of eliciting a serovar-specific response for each serovar. Several lines of evidence
suggest, however, that serovar-specific determinants have significant conforma-
tional attributes. First, immunization of rabbits with the synthetic peptide con-
jugates resulted in higher titers of antibody specific to the homologous synthetic
peptide, compared with the titers observed against homologous organisms .
Second, Zhang et al. (31) recently described two classes of serovar-specific mAbs
that recognize antigenic determinants of MOMP that can be differentiated by
their heat lability, although this attribute is not differentially associated with
neutralizing capabilities. The serovar-specific mAbs used in our study recognize
heat-stable determinants (7). Third, evaluations of secondary structure for this
sequence variable domain predict a high degree of turn and loop formation, in
addition to average hydrophilicity for each of the serovars despite extensive
amino acid changes (16).
Surface exposed loops are highly immunogenic and these are consequently
often targets of humoral immune response (26). A working model for the serovar-
specific domain of C. trachomatis MOMP consists of a surface protruding poly-
peptide loop with an antigenically variant apex (Fig. 7). This is also supported
by the observation that trypsin treatment of organisms readily destroys serovar-
specific antigens (31). Inspection of the amino acid sequence for Lys and Arg
residues (Fig. 7) shows that serovar B has a Lys residue within this sequence;
however, serovars L2 and C have Lys residues at the COOH-terminal end of the
loop, and serovar C has a second Lys residue at the N112-terminal end. Thus,
this entire domain must be prominently surface exposed to permit enzymatic
access to these residues. The organization of this domain is reminiscent of the
secondary structure of the variant gonococcal pilus antigen, which is also a loop
domain and this domain is stabilized by disulfide bonds (32). The specific cysteine
residues that form intramolecular disulfide bonds in MOMP are not known;
however, it is possible that the serovar-specific topographical loop domain may
be stabilized through the interaction of conserved cysteine residues (16).828
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FIGURE 7.
￿
Model of the serovar-specific antigenic domain. The proposed loop secondary
structure that protrudes from thesurfaceof theprotein is illustrated for serovar Ls with the
sequence differences for serovars C and B shown above . Solid lines for serovars B and C
indicate sequence identity to the serovar L2 sequence. Lys residues are shown in bold letters
as potential trypsin cleavage sites.
The mutually exclusive antigenic domains defined byourmAbsand polyvalent
antisera, while the most antigenically predominant, probably do not represent
the total antigenic repertoire . All exposed protein surfaces probably have some
immunogenic capacity, and probing with mAbs, perhaps with uncharacteristic
specificities, may reveal other less immunogenic sites . The crossreactivity of low
dilutions of the serovar C-type peptide antisera to other members of the C-
complex suggests that subspecies-specific antigenic determinants willbe identified
for this domain as well .
Using mAbs of predefined specificities and neutralizing capabilities, the iden-
tification of sequence defined determinants provides the opportunity for the
rational design ofimmunogenic determinants that possess the required structural
constraints to mimic the native conformation of protective determinants . Thus,
these efforts form the basis for developing recombinant or synthetic constructs
that may be tested for vaccine efficacy .
Since immunity to chlamydial infection is T cell dependent, it will also be
essential to define and provide chlamydial T helper cell determinants for vaccine
constructs that will promote natural boosting in endemic areas and elicit long-
term protection . It may be equally important to provide T cell determinants that
will be recognized by T cell subsets that elicit IL-5 and drive IgA differentiation
of peptide-specific B cells . One fundamental question is whether antigenic
diversity as a strategy used by many infectious agents to evade specific host
antibody response, is also an issue for T cell determinants . T cells recognize
protein domains that differ from the antigenic domains recognized by B cells,
and the antigenically diverse chlamydial MOMP family provides a useful model
system to address these questions . Interestingly, the MOMP has two domains
that display sequence variation among serovars that were not related to antigenic
domains using our mAbs or polyvalent antisera (I6) . Empirical evaluations using
strategies analogous to those used for mapping MOMP antibody determinants
may be used to identify dominant T cell determinants for this protein .
The principal surface protein antigen of Chlamydia trachomatis is the major
outermembrane protein (MOMP) . TheMOMP is antigenically complex . Amongthe 15 serovars of C. trachomatis, mAbs define serovar-, subspecies-, and species-
specific determinants on MOMP. The molecular basis of the antigenic diversity
of these proteins is reflected in amino acid variable sequence domains. We have
mapped the dominant topographic antigenic determinants of MOMP that are
defined by mAbs. Using recombinant DNA approaches we have identified the
linear distribution of two antigenic domains. One domain contains a serovar-
specific determinant and the other contains subspecies- and species-specific
determinants. These antigenic domains correspond to two amino acid sequence
variable domains. Synthetic peptides were immunogenic and these resolved the
serovar-specific determinant within a 14-amino acid peptide. The subspecies-
and species-specific determinants were overlapping within a 16-amino acid
peptide.
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